Please login to the form below

Not currently logged in
Email:
Password:

HCC

This page shows the latest HCC news and features for those working in and with pharma, biotech and healthcare.

FDA removes clinical hold on uniQure’s haemophilia gene therapy

FDA removes clinical hold on uniQure’s haemophilia gene therapy

Chronic infections with both HCV and HBV are associated with around 80% of HCC cases. ... Our comprehensive investigation showed that AMT-061 is very unlikely to have contributed to the HCC in our patient.

Latest news

  • Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

    It’s most recent approval was in hepatocellular carcinoma (HCC) that expresses high levels of the biomarker alpha-fetoprotein (AFP). ... Around 40% of patients with advanced HCC tumours express high levels of AFP – these tumours tend to be more

  • Exelixis bounces back with new prostate cancer data Exelixis bounces back with new prostate cancer data

    It is also approved for use under the name Cabometyx in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) – net product revenues from the entire franchise are expected to be between ... It is also testing cabozantinib in combination with

  • Roche files Tecentriq/Avastin combo in liver cancer Roche files Tecentriq/Avastin combo in liver cancer

    Roche has filed Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a first-line treatment for unresectable hepatocellular carcinoma (HCC) – the most common form of liver cancer. ... Patients received PD-L1 inhibitor Tecentriq plus

  • AZ’s Imfinzi scores orphan drug status in liver cancer AZ’s Imfinzi scores orphan drug status in liver cancer

    Out of that number of new cases, 42, 000 people were diagnosed with HCC in the US last year. ... According to AZ, HIMALAYA is the first trial to test dual immune checkpoint blockade in the first-line advanced HCC setting.

  • Roche’s Tecentriq/Avastin combo improves survival in liver cancer Roche’s Tecentriq/Avastin combo improves survival in liver cancer

    death by 42% compared to Bayer’s Nexavar (sorafenib) when given as a first-line therapy for hepatocellular carcinoma (HCC) patients ineligible for surgery. ... nivolumab), and Roche has a chance of pipping its rivals to the first-line HCC market.

More from news
Approximately 4 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Mining for results Mining for results

    The first product to come from Apixio's technology platform is called the HCC Profiler.

  • Pharma Perspectives: The agency selection process (part 2) Pharma Perspectives: The agency selection process (part 2)

    Samuel Hollis is a business unit director at AstraZeneca. In Pharma Perspectives, published in association with the HCC, senior industry and agency figures address key marketing challenges. ... The Health Communications' Council (HCC) is a specialist

  • Pharma Perspectives: The agency selection process (part 1) Pharma Perspectives: The agency selection process (part 1)

    In Pharma Perspectives, published in association with the HCC, senior industry and agency figures address key marketing challenges. ... The Health Communications' Council (HCC) is a specialist division of the European Association of Communications

  • Pharma perspectives: communications creativity (part 2) Pharma perspectives: communications creativity (part 2)

    David Higgins is UK managing director at Sudler &Hennessey Group. He can be contacted via email: David.Higgins@sudler.com  . In the PME/PMLiVE series Pharma Perspectives with the HCC  senior ... If you have a topic you'd like the series to explore

  • Pharma perspectives: communications creativity (part 1) Pharma perspectives: communications creativity (part 1)

    In the PME/PMLiVE series Pharma Perspectives with the HCC senior industry and agency figures give their thoughts on today's key marketing challenges. ... If you have a topic you'd like the series to explore please send it to editor@pmlive.com  . The

More from intelligence
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...